UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

Genes & development, 2007-12, Vol.21 (24), p.3214-3231

2007

Volltextzugriff (PDF)

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

Nature reviews. Cancer, 2010-04, Vol.10 (4), p.241

2010

Volltextzugriff (PDF)

Epidermal growth factor receptor mutations in lung cancer

Nature reviews. Cancer, 2007-03, Vol.7 (3), p.169-181

2007

Volltextzugriff (PDF)

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Cell, 2010-04, Vol.141 (1), p.69-80

2010

Volltextzugriff (PDF)

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (12), p.4853-4861

2008

Volltextzugriff (PDF)

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer

Cancer research (Chicago, Ill.), 2015-11, Vol.75 (22), p.4937-4948

2015

Volltextzugriff (PDF)

Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”

Biochemical pharmacology, 2010-09, Vol.80 (5), p.666-673

2010

Volltextzugriff (PDF)

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

Proceedings of the National Academy of Sciences - PNAS, 2007-12, Vol.104 (50), p.19936-19941

2007

Volltextzugriff (PDF)

Irreversible Inhibitors of the EGF Receptor May Circumvent Acquired Resistance to Gefitinib

Proceedings of the National Academy of Sciences - PNAS, 2005-05, Vol.102 (21), p.7665-7670

2005

Volltextzugriff (PDF)

A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes

Cancer cell, 2006-11, Vol.10 (5), p.425-435

2006

Volltextzugriff (PDF)

“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation

Clinical cancer research, 2006-07, Vol.12 (14), p.4392s-4395s

2006

Volltextzugriff (PDF)

Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe

Clinical cancer research, 2010-01, Vol.16 (1), p.109-120

2010

Volltextzugriff (PDF)

Allosteric inhibition of BCR-ABL

Cell cycle (Georgetown, Tex.), 2010-09, Vol.9 (18), p.3734-3738

2010

Volltextzugriff (PDF)

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

Clinical cancer research, 2008-11, Vol.14 (21), p.6867-6876

2008

Volltextzugriff (PDF)

Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol

Oncogene, 1998-05, Vol.16 (20), p.2639-2645

1998

Volltextzugriff (PDF)

"Oncogenic Shock": Turning an Activated Kinase against the Tumor Cell

Cell cycle (Georgetown, Tex.), 2006-12, Vol.5 (24), p.2878-2880

2006

Volltextzugriff (PDF)

ErbBs in lung cancer

Experimental cell research, 2009-02, Vol.315 (4), p.557-571

2009

Volltextzugriff (PDF)

A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay

Biochemical pharmacology, 2004-01, Vol.67 (2), p.227-234

2004

Volltextzugriff (PDF)

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

Nature genetics, 2005-12, Vol.37 (12), p.1315-1316

2005

Volltextzugriff (PDF)

Drug–target identification from total cellular lysate by drug-induced conformational changes

Analytical biochemistry, 2009-02, Vol.385 (2), p.314-320

2009

Volltextzugriff (PDF)

A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation

Oncotarget, 2011-06, Vol.2 (6), p.518-524

2011

Volltextzugriff (PDF)

Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma

Gastroenterology (New York, N.Y. 1943), 2009-05, Vol.136 (5), p.1741-1749.e6

2009

Volltextzugriff (PDF)

Development of radicicol analogues

Current cancer drug targets, 2003-10, Vol.3 (5), p.359

2003

Volltextzugriff (PDF)

Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors

Cancer research (Chicago, Ill.), 2009-05, Vol.69 (9), p.3937-3946

2009

Volltextzugriff (PDF)

High‐Throughput Lung Cancer Cell Line Screening for Genotype‐Correlated Sensitivity to an EGFR Kinase Inhibitor

Methods in Enzymology, 2008, Vol.438, p.331-341

2008

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(44)

Publikationsform

Sprache

Englisch
(48)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(37)
Humans
(29)
Oncology
(22)
Animals
(18)
Cell Biology
(17)
Biological And Medical Sciences
(15)
Biochemistry & Molecular Biology
(13)
Mice
(13)
Signal Transduction
(12)
Cell Line, Tumor
(10)
Cancer
(9)
Fundamental And Applied Biological Sciences. Psychology
(9)
Genetics & Heredity
(9)
Antineoplastic Agents - Pharmacology
(8)
Lung Neoplasms - Drug Therapy
(8)
Lung Neoplasms - Genetics
(8)
Molecular And Cellular Biology
(8)
Proteins
(8)
Lactones - Pharmacology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

Epidermal growth factor receptor mutations in lung cancer

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer

Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

Irreversible Inhibitors of the EGF Receptor May Circumvent Acquired Resistance to Gefitinib

A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes

“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation

Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe

Allosteric inhibition of BCR-ABL

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol

"Oncogenic Shock": Turning an Activated Kinase against the Tumor Cell

ErbBs in lung cancer

A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

Drug–target identification from total cellular lysate by drug-induced conformational changes

A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation

Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma

Development of radicicol analogues

Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors

High‐Throughput Lung Cancer Cell Line Screening for Genotype‐Correlated Sensitivity to an EGFR Kinase Inhibitor

Suchergebnisse filtern